GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Total Liabilities

Ceapro (TSXV:CZO) Total Liabilities : C$3.59 Mil (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Ceapro Total Liabilities?

Ceapro's Total Liabilities for the quarter that ended in Dec. 2023 was C$3.59 Mil.

Ceapro's quarterly Total Liabilities increased from Jun. 2023 (C$3.54 Mil) to Sep. 2023 (C$3.98 Mil) but then declined from Sep. 2023 (C$3.98 Mil) to Dec. 2023 (C$3.59 Mil).

Ceapro's annual Total Liabilities increased from Dec. 2021 (C$3.33 Mil) to Dec. 2022 (C$5.45 Mil) but then declined from Dec. 2022 (C$5.45 Mil) to Dec. 2023 (C$3.59 Mil).


Ceapro Total Liabilities Historical Data

The historical data trend for Ceapro's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Total Liabilities Chart

Ceapro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.96 4.91 3.33 5.45 3.59

Ceapro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.45 4.61 3.54 3.98 3.59

Ceapro Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ceapro's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.738+(1.852+0.0010000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3.59

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=31.446-27.855
=3.59

Ceapro's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.738+(1.852+0.0010000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3.59

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=31.446-27.855
=3.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ceapro Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ceapro's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Ceapro (TSXV:CZO) Business Description

Traded in Other Exchanges
Address
7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2
Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines